Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change $ Change
grade B $123.22 -0.12% -0.15
CELG closed down 0.12 percent on Thursday, March 23, 2017, on 68 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical CELG trend table...

Date Alert Name Type % Chg
Mar 23 NR7 Range Contraction 0.00%
Mar 23 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.12%
Mar 20 Slingshot Bullish Bullish Swing Setup -2.60%
Mar 17 New 52 Week High Bullish -2.03%
Mar 15 New 52 Week High Bullish -2.88%
Mar 15 Stochastic Reached Overbought Other -2.88%
Mar 15 New Uptrend Bullish -2.88%
Mar 14 NR7 Range Contraction -1.17%
Mar 14 Cup with Handle Other -1.17%

Older signals for CELG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company’s commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company’s pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Is CELG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 127.64
52 Week Low 94.42
Average Volume 4,115,446
200-Day Moving Average 111.5795
50-Day Moving Average 119.164
20-Day Moving Average 123.8095
10-Day Moving Average 124.93
Average True Range 2.3407
ADX 28.03
+DI 21.6
-DI: 16.42
Chandelier Exit (Long, 3 ATRs) 120.6179
Chandelier Exit (Short, 3 ATRs) 124.3021
Upper Bollinger Band 127.6418
Lower Bollinger Band 119.9772
Percent B (%b) 0.42
Bandwidth 0.061906